Psychedelics Today PT582 – Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule DOI and DOC, with Hamilton Morris
Jan 21, 2025
Hamilton Morris, a renowned chemist, filmmaker, and journalist, dives into the crucial issues surrounding the DEA's attempts to classify DOI and DOC as Schedule I substances. He shares his firsthand experiences from a DEA hearing, exposing the bureaucratic mess that stifles psychedelic research. Morris discusses the safety profiles of these compounds, the frustrating exclusion of expert testimonials in court, and the environmental concerns tied to Sonoran Desert toad venom use. This eye-opening conversation emphasizes the pressing need for improved drug policy and advocacy for scientific progress.
AI Snips
Chapters
Transcript
Episode notes
Hamilton Morris's Courtroom Experience
- Hamilton Morris discusses the DEA's attempt to schedule DOI and DOC.
- He details his courtroom experience alongside advocates from SSDP and other groups.
DEA's Overreach
- The DEA holds excessive power, creating and enforcing laws, leading to potential corruption.
- The Controlled Substances Act now includes non-drugs like P2P, PCC, and 2C-H, highlighting this overreach.
DOI's Importance in Research
- DOI is crucial for psychedelic and serotonergic research.
- Many researchers actively use this molecule, highlighting its significance.